AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.

Oncology revenue reached $22.4 billion in 2024, with Tagrisso, Lynparza, and Enhertu delivering strong growth. Enhertu's revenue grew 54% in Q4, supported by expanded indications, including HER2 low ...

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business impact of the Chinese investigations remains minor.

A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super Bowl ...

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities investigate the company’s former China head. | As AstraZeneca faces an ongoing ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

The boss of AstraZeneca has denied a rift with the Government after axing plans for a £450m vaccine factory in Liverpool ...

AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter sales of $14.89 billion, up 18% year over year (+19% at constant ...

Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...

The boss of drugmaker AstraZeneca has said he was “very disappointed” with the firm’s move to scrap plans for a £450 million ...

AstraZeneca Plc reported better-than-expected profit and revenue in the fourth quarter and forecast further gains, helped by ...